Purpose of review Proton pump inhibitors (PPI) are one of most frequently prescribed drugs in the world. The purpose of this review is to describe the hypersensitivity reactions to PPI.
INTRODUCTION
PPI are commonly used for the treatment of acidrelated disorders such as gastroesophageal reflux disease, peptic ulcer disease and associated Helicobacter pylori infection, as they are potent inhibitors of gastric acid secretion. PPI are generally well tolerated. However, there have been some concerns about potential safety issues related to PPI usage [1 && ]. When used during H. pylori eradication, drug allergy due to concomitant antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole, tetracyclines) used in triple therapy will also need to be excluded.
Potential safety issues associated with PPI are clopidogrel interaction [unclear but FDA has cautioned against the use of omeprazole (and esomeprazole) by clopidogrel users], Clostridium difficile/ other enteric infections (probable), pneumonia (probable), hypomagnesemia (rare), idiosyncratic reactions such as acute interstitial nephritis/ hepatitis (rare), anaphylaxis (rare), cytochrome P450 interaction (negligible), rebound hypersecretion (negligible), fractures (negligible), and pregnancy risk (likely negligible) [1
& ]. PPI also may increase the risk of developing food allergy or IgEmediated drug allergy in that inhibition or neutralization of gastric acid allow persistence of intact food allergens and protein-bound oral drugs with enhanced capacity to sensitize and elicit allergic reactions via the oral route [3 && ,4]. This review will mainly focus on allergic and nonallergic hypersensitivity reactions to PPI. The clinical manifestations of PPI-induced hypersensitivity reactions are as follows:
(1) Urticaria, angioedema, and anaphylaxis, (2) Cytopenia, (3) Vasculitis, (4) Acute allergic interstitial nephritis, (5) Contact dermatitis (occupational), (6) Photoallergic dermatitis, (7) Maculopapular eruption, (8) Erythroderma, (9) DRESS syndrome, (10) Stevens-Johnson syndrome/Toxic epidermal necrolysis, and (11) Other autoimmune reactions (including lupus erythematosus).
STRUCTURE OF PROTON PUMP INHIBITORS AND POSSIBLE MECHANISMS FOR HYPERSENSITIVITY
Most of PPI are weak bases composed of two moieties: a substituted pyridine and a benzimidazole.
Tenatoprazole that has a longer half-life is an imidazopyridine-derivative. Protonation of the benzimidazole or imidazopyridine activates these pro-drugs, converting them to sulfenic acids/sulfonamides that react covalently with one or more cysteines accessible from the luminal surface of the ATPase (Fig. 1 ) [5, 6] . Although the exact mechanism for PPI-induced hypersensitivity reactions is not revealed yet, three mechanisms such as hapten, prohapten, and the p-i concept may play roles in the pathogenesis [ ]. The onset of symptoms ranged from minutes to hours. The largest case series reported nine patients with omeprazole allergy: urticaria/angioedema in seven and anaphylaxis in two patients. Eight of the patients (88.9%) showed positive responses to omeprazole with skin prick tests or intradermal tests, which suggested IgE-mediated hypersensitivity. Four patients also showed a positive response to pantoprazole with skin prick test. However, only one patient showed a positive response to pantoprazole during drug provocation testing. Lansoprazole was well tolerated in this study: no one showed positive response with skin prick test or with controlled challenge test. This case series suggested that skin tests and controlled challenge tests should be performed before offering well tolerated alternative drugs [6] .
A case of pantoprazole-induced anaphylaxis during general anesthesia has been reported with positive skin tests to pantoprazole demonstrated [12] .
A high level of clinical suspicion and temporal relationship is critical in the diagnosis of PPI-induced hypersensitivity reactions. Skin tests (prick/intradermal test) and controlled challenge tests are helpful in the diagnosis of type I hypersensitivity reactions by PPI. Recently it has been proposed that basophil activation test (BAT) could be helpful in the diagnosis of IgEmediated allergic reactions to PPI as an in-vitro study [6, 10] .
PROTON PUMP INHIBITOR-INDUCED CYTOPENIA
Cytopenia such as neutropenia and agranulocytosis are rare adverse events associated with PPI treatment. Most of previously published cases of isolated neutropenia have involved omeprazole: a case of omeprazole-induced neutropenia with further recurrence upon pantoprazole treatment has been recently published, which suggested a possible cross-reactivity between omeprazole and pantoprazole. Leukopenia is described as a possible adverse effect in the summary of product characteristics of PPIs [14] . PPI-induced thrombocytopenia, which is rare but could be severe, has also been reported [15, 16] . However, one study [16] showed there was no difference in the occurrence of thrombocytopenia between pantoprazole (6.2%) and control group (6.6%). Hemolytic anemia after PPI use also has been reported, in which hemoglobin level was restored after the discontinuation of omeprazole [17] .
Although the exact mechanisms are not revealed yet, the possible mechanisms to explain the pathogenesis of PPI-induced cytopenia could be toxic or immune-mediated (type II hypersensitivity reactions) mechanisms [11 && ].
KEY POINTS
Hypersensitivity reactions to PPI may be immediate or nonimmediate.
Skin prick and intradermal tests may be useful in immediate reactions and diagnosis of potential crossreactivities.
A high level of clinical suspicion is essential in the diagnosis of PPI-induced hypersensitivity reactions.
Physicians should be aware of the possible hypersensitivity reactions due to PPI.
Routine prescription for PPI should be strongly discouraged.
PROTON PUMP INHIBITOR-INDUCED VASCULITIS
Cases of PPI-induced vasculitis (not only cutaneous but also systemic vasculitis) have been reported. Jacobs-Kosmin et al. [17] reported a case of perinuclear antineutrophil cytoplasmic antibody-associated vasculitis with interstitial nephritis, cutaneous vasculitis in association with pantoprazole. The authors also summarized 12 prior cases of autoimmune manifestations other than interstitial nephritis. Recently a case of Henoch-Schonlein purpura with rapidly progressive glomerulonephritis secondary to pantoprazole ingestion has been reported. Clinical manifestation included terminal ileitis and rapidly progressing glomerulonephritis, which progressed to renal failure requiring hemodialysis, and intravenous pulse steroids. His renal function recovered after treatment with mycophenolate mofetil [18] .
PROTON PUMP INHIBITOR-INDUCED ACUTE ALLERGIC INTERSTITIAL NEPHRITIS
The clinical presentation of acute allergic interstitial nephritis (AIN) can vary; a high level of clinical suspicion is critical for the diagnosis. However, patients typically present with general symptoms of renal failure such as nausea, vomiting and fatigue. Injury to the medulla can inhibit the ability to concentrate urine, leading to polyuria and polydipsia. Other clinical manifestations of AIN include acute elevation in creatinine levels not because of prerenal or postrenal causes, maculopapular rash, proteinuria, pyuria (in almost all cases), hematuria (in 90% of cases), and eosinophiluria (in 80% of cases). Timely diagnosis is important because early intervention (withdrawal of PPI promptly in the first week) improves the outcome [19 && ]. In a systematic review, Sierra et al. [20] analyzed 64 cases of PPI-associated AIN from 1970 to 2006, 59 of which were proven by biopsy and one by recurrence of AIN upon reinitiating PPI. Renal function recovered within a mean of 35.5 weeks (24-52 weeks) after withdrawal of PPI therapy. Evidence for causality in the cases reviewed was often poor. Reintroduction of the suspected PPI was not done for ethical reasons. All of the PPI were implicated, suggesting a class effect. 
PROTON PUMP INHIBITOR-INDUCED CONTACT DERMATITIS
Five cases of occupational airborne contact dermatitis caused by omeprazole, lansoprazole, and pantoprazole in the setting of the pharmaceutical industry have been reported so far (Table 1) [19 && , [20] [21] [22] . All of the patients were male and the mean age was 42.2 AE 15.8 years. Mean duration of exposure before symptom development was 5.6 AE 1.9 years. The involved areas were mainly eyelids, face, neck, arm, and hands, which suggest the route of sensitization could be airborne contact or inhalation. It is important for pharmaceutical workers to wear protective equipment such as overalls, masks, and gloves. Patch test gave good positive responses to the offending drugs [21] [22] [23] [24] .
PPI can also cause photoallergic dermatitis. The involved area is usually face and arms. So far, very few cases were reported with omeprazole, rabeprazole, pantoprazole, and esomeprazole [25] .
PROTON PUMP INHIBITOR-INDUCED DRESS SYNDROME
Cutaneous reactions to PPI are usually mild and include maculopapular eruptions, pruritus, and urticaria. A case of drug rash with eosinophilia and systemic symptoms (DRESS) from esomeprazole has been reported. Cross-reactivity among almost all other PPI were supported by patch test showing positive responses to esomeprazole, omeprazole, rabeprazole, and lansoprazole but not to rabeprazole. Interestingly the patient experienced a mild erythroderma with facial edema and desquamation 60 h after skin patch test, which lasted for 4 days, requiring treatment with topical steroids and emollients. This case suggests that skin patch tests may induce a flare of DRESS [26 && ].
PROTON PUMP INHIBITOR-INDUCED STEVENS-JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS
Case reports of toxic epidermal necrolysis (TEN) after omeprazole 3 weeks later, [27] and lansoprazole have been reported [28] . Stevens Johnson syndrome following the use of PPI have not been reported in the English literature.
OTHER AUTOIMMUNE MANIFESTATIONS FROM PROTON PUMP INHIBITOR
Cases of PPI-associated lupus erythematosus have been reported. A recent systematic review identified two cases of lansoprazole-associated subacute cutaneous lupus erythematosus and reported that 
DESENSITIZATION IN PROTON PUMPS INHIBITOR ALLERGY
There is only one case report on desensitization with PPI [31] . They dissolved the granules of omeprazole in bicarbonate and created 10-fold serial dilutions. The starting dose was 0.001 mg (0.5 mL of 0.002 mg/mL solution: 1 : 10 000 of the final required dose). They escalated doses twofold, at 20-min intervals until final dose of 16 mg was reached after 5.6 h. One hour later, the patient could take 20 mg of ompeprazole and tolerated 2 weeks of the full therapeutic treatment for H. pylori eradication.
CONCLUSION
Hypersensitivity reactions to PPI may be immediate or nonimmediate reactions, and vary from mild symptoms to life-threatening disorders. A high level of clinical suspicion is critical in the diagnosis of PPI-induced hypersensitivity reactions. Physicians should be aware of the possibility of hypersensitivity reactions to PPI, the mechanisms of which remain largely unknown.
